3SBio (HKG:1530) said its 707 injection was granted a breakthrough therapy designation by China's National Medical Products Administration, according to a late Thursday bourse filing.
This designation provides benefits for 707's development as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small cell lung cancer, the filing stated.
Drugs with that designation are entitled to policy support, prioritized communication resources, enhanced guidance, and accelerated development.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。